An overview of interleukin-1 receptor Antagonist, Anakinra, in the treatment of cutaneous diseases

Current Clinical Pharmacology

Volumn 7, Issue 4, 2012, Pages 271-275

  Pazyar, Nader ^a   Feily, Amir ^b   Yaghoobi, Reza ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b JAHROM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anakinra; Dermatology; Interleukin 1 receptor antagonist; Review

Indexed keywords

CANAKINUMAB; COLCHICINE; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1ALPHA; STEROID;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALLERGIC REACTION; ATOPIC DERMATITIS; CYTOPHAGIC HISTIOCYTIC PANNICULITIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GRANULOMATOUS SKIN DISEASE; HUMAN; INFECTION; INJECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LAMELLAR ICHTHYOSIS; MELANOMA; MUCKLE WELLS SYNDROME; NEUTROPHILIC PANNICULITIS; NONHUMAN; PANNICULITIS; PAPA SYNDROME; PATHOGENESIS; PHOTOAGING; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; SAPHO SYNDROME; SCHNITZLER SYNDROME; SKIN DISEASE; SKIN TOXICITY; SUPPURATIVE HIDRADENITIS;

EID: 84867802417     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488412803305821     Document Type: Review

References (49)

1. Mee JB, Antonopoulos C, Poole S, Kupper TS, Groves RW. Counter-regulation of interleukin-1alpha (IL-1alpha) and IL-1 receptor antagonist in murine keratinocytes. J Invest Dermatol 2005; 124: 1267-74.
2. [cited 2012 March 9]. Available from: http://en.wikipedia.org/wiki/ IL1.
3. [cited 2012 March 9]. Available from: http://en.wikipedia.org/wiki/ File:31BI.png.
4. Hart K, Haugen A, Zienolddiny S. Allele-specific induction of IL1B-31T/C promoter polymorphism by lung carcinogens. Mutat Res 2008; 656: 14-8.
5. Nakajima A, Matsuki T, Komine M, et al. TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-/-mice. J Immunol 2010; 185: 1887-93.
6. Kong J, Grando SA, Li YC. Regulation of IL-1 family cytokines IL-1alpha, IL-1 receptor antagonist, and IL-18 by 1,25-dihydroxyvitamin D3 in primary keratinocytes. J Immunol 2006; 176: 3780-7.
7. Fiocco U, Vezzù M, Cozzi L, Todesco S. IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy. Reumatismo 2004; 56(1 Suppl 1): 62-73.
8. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci 2009; 1182: 111-23.
9. Le GT, Abbenante G. Inhibitors of TACE and Caspase-1 as antiinflammatory drugs. Curr Med Chem 2005; 12: 2963-77.
10. Kaiser C, Knight A, Nordström D, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012; 32: 295-9.
11. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003; 74: 85-94.
12. Juanola X, Rodríguez V, Dios D. Drugs employed during pregnancy and contraceptive methods in rheumatic disease. New evidence. Reumatol Clin 2010; 6: 43-8.
13. Pazyar N, Yaghoobi R. Ginkgo biloba extract: a novel addition to antipsoriasis ammunition? J Altern Complement Med 2012; 18: 1-2.
14. Pazyar N, Yaghoobi R, Kazerouni A, Feily A. Oatmeal in dermatology: A brief review. Indian J Dermatol Venereol Leprol 2012; 78: 142-5.
15. Feily A, Pazyar N, Khazanee A, Ghassemi MR, Rafiee E, Safarpoor M. Potential advantages of topical phenytoin as a novel anti psoriasis arsenal. Niger J Med. 2011; 20: 296-297.
16. Renne J, Schäfer V, Werfel T, Wittmann M. Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation. Br J Dermatol 2010; 162: 1198-205.
17. Gartlehner G, Thieda P, Morgan LC, Thaler K, Hansen RA, Jonas B. Drug Class Review: Targeted Immune Modulators: Final Report Update 2 [Internet]. Portland (OR): Oregon Health & Science University 2009 Nov.
18. Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010; 153: 66-7.
19. Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010; 29: 1169-73.
20. Herz U, Bunikowski R, Renz H. Role of T cells in atopic dermatitis. New aspects on the dynamics of cytokine production and the contribution of bacterial superantigens. Int Arch Allergy Immunol 1998; 115: 179-90.
21. Wang X, Bi Z, Chu W, Wan Y. IL-1 receptor antagonist attenuates MAP kinase/AP-1 activation and MMP1 expression in UVAirradiated human fibroblasts induced by culture medium from UVB-irradiated human skin keratinocytes. Int J Mol Med 2005; 16: 1117-24.
22. Karrer S, Bosserhoff AK, Weiderer P, Landthaler M, Szeimies RM. Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. Br J Dermatol 2004; 151: 776-83.
23. McKenzie RC, Oran A, Dinarello CA, Sauder DN. Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo. Anticancer Res 1996; 16: 437-41.
24. Triozzi PL, Aldrich W. Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. Anticancer Res 2010; 30: 345-54.
25. Eiling E, Schröder JO, Gross WL, Kreiselmaier I, Mrowietz U, Schwarz T. The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy--an autoinflammatory syndrome? J Dtsch Dermatol Ges 2008; 6: 626-31.
26. Cascavilla N, Bisceglia M, D'Arena G. Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial. Int J Immunopathol Pharmacol 2010; 23: 633-6.
27. Besada E, Nossent H. Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. Clin Rheumatol 2010; 29: 567-71.
28. Gran JT, Midtvedt Ø, Haug S. A woman with recurrent urticaria, joint pain and fever. Tidsskr Nor Laegeforen 2011; 131: 135-36.
29. Schuster C, Kränke B, Aberer E, Arbab E, Sturm G, Aberer W. Schnitzler syndrome: response to anakinra in two cases and a review of the literature. Int J Dermatol. 2009; 48: 1190-94.
30. Crouch R, Akhras V, Sarkany R. Schnitzler's syndrome: successful treatment with anakinra. Australas J Dermatol 2007; 48: 178-81.
31. Eiling E, Möller M, Kreiselmaier I, Brasch J, Schwarz T. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 2007; 57: 361-4.
32. Wollina U, Haroske G. Pyoderma gangraenosum. Curr Opin Rheumatol 2011; 23: 50-6.
33. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161: 1199-01.
34. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010; 146: 1265-70.
35. O'Shaughnessy RF, Choudhary I, Harper JI. Interleukin-1 alpha blockade prevents hyperkeratosis in an in vitro model of lamellar ichthyosis. Hum Mol Genet 2010; 19: 2594-605.
36. Kluger N, Gil-Bistes D, Guillot B, Bessis D. Efficacy of Anti-Interleukin-1 Receptor Antagonist Anakinra (Kineret®) in a Case of Refractory Sweet's Syndrome. Dermatology 2011; 222: 123-7.
37. Lipsker D, Perrigouard C, Foubert A, Cribier B. Anakinra for difficult-to-treat neutrophilic panniculitis: IL-1 blockade as a promising treatment option for neutrophil-mediated inflammatory skin disease. Dermatology 2010; 220: 264-7.
38. Aronson IK, Worobec SM. Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview. Dermatol Ther 2010; 23: 389-402.
39. Madan V, Kingston H, Jamieson LA, Goyal N, Ead R. Muckle-Wells syndrome/neonatal-onset multisystem inflammatory disease overlap associated with myelodysplasia and cerebrovascular accident. Clin Exp Dermatol 2010; 35: 752-5.
40. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011; 63: 840-9.
41. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 2009; 146: 467-78.
42. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I. Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature. Semin Arthritis Rheum 2011; 41: 265-71.
43. Eleftheriou D, Gerschman T, Sebire N, Woo P, Pilkington CA, Brogan PA. Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford) 2010; 49: 1505-12.
44. O'Connell SM, O'Regan GM, Bolger T, et al. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 2007; 24: 85-9.
45. Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006; 142: 1591-7.
46. Ross JB, Finlayson LA, Klotz PJ, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008; 12: 8-16.
47. Vila AT, Puig L, Fernández-Figueras MT, Laiz AM, Vidal D, Alomar A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol 2005; 153: 417-23.
48. Regula CG, Hennessy J, Clarke LE, et al. Interstitial granulomatous drug reaction to anakinra. J Am Acad Dermatol 2008; 59(2 Suppl 1): S25-7.
49. Regula CG, Hennessy J, Clarke LE, et al. Interstitial granulomatous drug reaction to anakinra. J Am Acad Dermatol 2008; 59(2 Suppl 1): S25-7.